Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2015 Aug;100(8):3202-9. doi: 10.1210/jc.2015-2122. Epub 2015 Jun 17.

Paraganglioma in Pregnancy: A Case Series and Review of the Literature.

Author information

1
Departments of Endocrinology (L.A.W., J.V.C., M.S.E.) and Surgery (G.Y.M.-R.), Waikato Hospital, and Waikato Clinical Campus (J.V.C., G.Y.M.-R., M.S.E.), University of Auckland, Hamilton 3240, New Zealand.

Abstract

CONTEXT:

Pregnancies complicated by a pheochromocytoma or paraganglioma are very rare, being estimated to occur in 0.007% of all pregnancies. Both the well-being of the mother and fetus need to be considered, and management can be challenging. The optimal management of women with a pheochromocytoma or paraganglioma in pregnancy is not well established.

OBJECTIVE:

The objective of the study was to assess whether there is a difference in fetal or maternal mortality between pheochromocytomas and paragangliomas in pregnancy.

DESIGN:

We present an experience of eight pregnancies in four SDHB germline mutation-positive women with sympathetic paragangliomas, followed by a systematic review of the literature to compare the outcome of paragangliomas with that of pheochromocytomas occurring in pregnancy.

RESULTS:

In our case series, favorable fetal and maternal outcomes were seen in all eight pregnancies. From the systematic review, maternal and fetal mortality were lower in women with paragangliomas, at 3.6% and 12% respectively, compared with 9.8% and 16% in women with pheochromocytomas.

CONCLUSION:

Pregnant women with paragangliomas may be at a lower risk of adverse outcome than those with pheochromocytomas, but both maternal and fetal mortality rates are still higher than that of the general obstetric population.

PMID:
26083822
DOI:
10.1210/jc.2015-2122
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center